Donation

Understanding DARZALEX and DARZALEX FASPRO

Darzalex® (daratumumab) is the first monoclonal antibody approved by the FDA that targets the CD38 protein on the surface of myeloma cells, causing myeloma cell death. Darzalex Faspro® (daratumumab + hyaluronidase-fihj) is a newer formulation of this targeted therapy. There are numerous FDA-approved regimens with Darzalex or Darzalex Faspro that are used throughout the myeloma disease course - from frontline therapy to the relapsed and refractory setting - and many ongoing myeloma clinical trials are investigating additional indications.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.